Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The second sialic acid-binding site (SBS) is a non-catalytic pocket located on the surface of the Influenza A virus neuraminidase (NA) protein, distinct from the primary catalytic site (Vavricka et al., 2011, Nature). While the primary site is responsible for cleaving sialic acid to allow viral release, the SBS facilitates the initial binding and walking of the virus across the sialylated host cell surface and through the mucus layer (Du et al., 2019, J. Virol.). This site is highly conserved in avian influenza viruses (N1, N2, N3, N5, N6, N7, N9) and was present in the 1918 pandemic H1N1 strain, though it has been lost in many subsequent human seasonal lineages (Zhu et al., 2012, Nat. Commun.). Research suggests that the SBS plays a crucial role in viral fitness and host-range adaptation by modulating the balance between hemagglutinin binding and neuraminidase cleavage (Benton et al., 2015, J. Biol. Chem.). As a therapeutic target, the SBS offers a strategy to combat resistance to traditional neuraminidase inhibitors like oseltamivir, which only target the catalytic site (Vavricka et al., 2013, PLOS Pathogens). Experimental multivalent inhibitors designed to bind both the primary and secondary sites have shown promise in neutralizing a broader range of influenza strains by increasing avidity and blocking viral motility (Zhang et al., 2018, Bioconjug. Chem.).
Inhibition of viral motility and attachment by blocking the non-catalytic sialic acid-binding site on the neuraminidase protein.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus neuraminidase (secondary sialic acid-binding site) (NA-SBS).